PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016

GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Wednesday, May 4, 2016.

Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities.

Conference call details are as follows:

Date: Wednesday, May 4, 2016
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 95870834
Via web: www.novavax.com, “Investors”/ “Events”
   

Conference call replay:

Dates: Starting at 7:00 p.m. ET, May 4, 2016 until midnight May 11, 2016
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 95870834
Via web: www.novavax.com, “Investors”/ “Events”
   

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:
Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

Primary Logo

Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept